drugset / Trial / NCT00961844

Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma

NCT00961844

Phase 1/2 Terminated 15 enrolled Steinar Aamdal
Non-randomizedSingle-groupOpen-labelTreatment

Summary

In this trial the investigators want to combine chemotherapy with immunotherapy by giving the patients Temozolomide, before vaccination. The investigators have also included hTERT and survivin mRNA in the vaccine. Finally, the investigators want to introduce ex vivo T cell expansion after lymphodepletion for the patients who show an immune response.

Timeline

Start
2009-08
Primary completion
2012-06
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Dendritic cells Cell therapy
Subject Temozolomide Small molecule

Indications